FOSB

Summary

FOSB (FosB proto-oncogene, AP-1 transcription factor subunit, HGNC:3797) is a protein-coding gene on chromosome 19q13.32, encoding Protein FosB (P53539). Heterodimerizes with proteins of the JUN family to form an AP-1 transcription factor complex, thereby enhancing their DNA binding activity to gene promoters containing an AP-1 consensus sequence 5’-TGA[GC]TCA-3’ and enhancing their transcriptional activity.

The Fos gene family consists of 4 members: FOS, FOSB, FOSL1, and FOSL2. These genes encode leucine zipper proteins that can dimerize with proteins of the JUN family, thereby forming the transcription factor complex AP-1. As such, the FOS proteins have been implicated as regulators of cell proliferation, differentiation, and transformation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 2354 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 44 total
• GTEx eGene: eQTL in 3 tissues, sQTL in 1 (q < 0.05)
• Constraint (gnomAD): pLI 0.95 (loss-of-function intolerant), LOEUF 0.53 (moderately constrained)
• Transcription factor: yes — 43 downstream targets (CollecTRI)
• MANE Select transcript: NM_006732
• Interaction hub: 2,250 STRING partners (top 5% of genes corpus-wide)

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3797
Approved symbol	FOSB
Name	FosB proto-oncogene, AP-1 transcription factor subunit
Location	19q13.32
Locus type	gene with protein product
Status	Approved
Aliases	G0S3, GOSB, GOS3, AP-1, MGC42291, DKFZp686C0818
Ensembl gene	ENSG00000125740
Ensembl biotype	protein_coding
OMIM	164772
Entrez	2354

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 11 protein_coding, 2 retained_intron

MANE Select: ENST00000353609

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 8, TSL 2: 1, TSL 5: 2

ENST00000353609, ENST00000417353, ENST00000443841, ENST00000585836, ENST00000586113, ENST00000586615, ENST00000587358, ENST00000589593, ENST00000590335, ENST00000591858, ENST00000592436, ENST00000592811, ENST00001135595

RefSeq mRNA: 3 — MANE Select: NM_006732 NM_001114171, NM_001411069, NM_006732

CCDS: CCDS12664, CCDS46113, CCDS92643

Canonical transcript exons

ENST00000353609 — 4 exons

Exon	Start	End
ENSE00000858216	45471194	45471301
ENSE00002785923	45467996	45468712
ENSE00003534885	45470629	45470949
ENSE00004787042	45472551	45475179

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 99.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 147.2039 / max 19108.8961, expressed in 1523 samples.

Highest expression (Bgee): mucosa of stomach, upper leg skin, gall bladder, saphenous vein, nipple.

Genetic regulation across tissues (GTEx eQTL / sQTL)

FOSB is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 3 tissues and its splicing (sQTL) in 1 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

4 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Brain Cortex	eqtl	2.5e-03	+2.10	19:46336995:T:A
Skin Sun Exposed Lower leg	eqtl	2.2e-02	-0.66	19:46347744:G:T
Whole Blood	eqtl	2.2e-02	-0.25	19:45985160:C:T
Esophagus Gastroesophageal Junction	sqtl	4.3e-02	-1.50	19:44488416:C:T

FANTOM5 promoters

showing 10 of 24 alternative TSS:

Promoter ID	TPM avg	Samples expressed
176431	144.5626	1485
176438	1.2051	382
176477	0.1941	85
176456	0.1460	65
176447	0.1390	54
176452	0.1089	34
176453	0.0979	38
176476	0.0950	46
176439	0.0674	18
176454	0.0644	13

Top tissues by expression

showing 100 of 285 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
mucosa of stomach	UBERON:0001199	99.67	gold quality
upper leg skin	UBERON:0004262	99.29	gold quality
gall bladder	UBERON:0002110	99.21	gold quality
saphenous vein	UBERON:0007318	99.14	gold quality
nipple	UBERON:0002030	99.00	gold quality
vena cava	UBERON:0004087	98.91	gold quality
granulocyte	CL:0000094	98.68	gold quality
mucosa of urinary bladder	UBERON:0001259	98.31	gold quality
mucosa of paranasal sinus	UBERON:0005030	97.16	gold quality
bone marrow cell	CL:0002092	96.62	gold quality
penis	UBERON:0000989	96.12	gold quality
trachea	UBERON:0003126	95.99	gold quality
left uterine tube	UBERON:0001303	95.41	gold quality
urethra	UBERON:0000057	95.07	gold quality
smooth muscle tissue	UBERON:0001135	94.89	gold quality
epithelium of mammary gland	UBERON:0003244	94.63	gold quality
mammary duct	UBERON:0001765	94.29	gold quality
cervix epithelium	UBERON:0004801	93.85	gold quality
skin of abdomen	UBERON:0001416	93.71	gold quality
cervix squamous epithelium	UBERON:0006922	93.53	gold quality
cardia of stomach	UBERON:0001162	93.36	gold quality
vermiform appendix	UBERON:0001154	92.58	gold quality
right ovary	UBERON:0002118	91.01	gold quality
trigeminal ganglion	UBERON:0001675	90.92	gold quality
synovial joint	UBERON:0002217	90.58	gold quality
oviduct epithelium	UBERON:0004804	90.58	gold quality
seminal vesicle	UBERON:0000998	90.57	gold quality
blood vessel layer	UBERON:0004797	90.17	gold quality
caecum	UBERON:0001153	89.87	gold quality
fallopian tube	UBERON:0003889	89.82	gold quality
lower lobe of lung	UBERON:0008949	89.55	silver quality
cardiac muscle of right atrium	UBERON:0003379	89.45	gold quality
monocyte	CL:0000576	89.32	gold quality
parotid gland	UBERON:0001831	88.99	gold quality
omental fat pad	UBERON:0010414	88.77	gold quality
peritoneum	UBERON:0002358	88.71	gold quality
sperm	CL:0000019	88.60	silver quality
mononuclear cell	CL:0000842	88.59	gold quality
male germ cell	CL:0000015	88.47	silver quality
rectum	UBERON:0001052	88.29	gold quality
leukocyte	CL:0000738	88.17	gold quality
layer of synovial tissue	UBERON:0007616	87.48	gold quality
sural nerve	UBERON:0015488	87.41	gold quality
adipose tissue of abdominal region	UBERON:0007808	87.36	gold quality
hindlimb stylopod muscle	UBERON:0004252	87.17	gold quality
secondary oocyte	CL:0000655	86.72	gold quality
ascending aorta	UBERON:0001496	86.52	gold quality
thoracic aorta	UBERON:0001515	86.43	gold quality
lymph node	UBERON:0000029	85.94	gold quality
buccal mucosa cell	CL:0002336	85.89	gold quality
left ovary	UBERON:0002119	85.80	gold quality
lung	UBERON:0002048	85.64	gold quality
epithelial cell of pancreas	CL:0000083	85.62	gold quality
right coronary artery	UBERON:0001625	85.58	gold quality
ovary	UBERON:0000992	85.30	gold quality
nephron tubule	UBERON:0001231	85.22	gold quality
gingival epithelium	UBERON:0001949	84.44	gold quality
upper lobe of left lung	UBERON:0008952	84.40	gold quality
oocyte	CL:0000023	84.27	gold quality
kidney epithelium	UBERON:0004819	84.07	gold quality
skin of hip	UBERON:0001554	83.95	gold quality
zone of skin	UBERON:0000014	83.91	gold quality
superficial temporal artery	UBERON:0001614	83.82	gold quality
metanephric glomerulus	UBERON:0004736	83.66	gold quality
cartilage tissue	UBERON:0002418	83.56	gold quality
pancreatic ductal cell	CL:0002079	83.53	silver quality
renal glomerulus	UBERON:0000074	83.50	gold quality
upper lobe of lung	UBERON:0008948	83.41	gold quality
cardiac atrium	UBERON:0002081	83.39	gold quality
pharyngeal mucosa	UBERON:0000355	83.20	gold quality
right atrium auricular region	UBERON:0006631	82.54	gold quality
fundus of stomach	UBERON:0001160	82.52	gold quality
skin of leg	UBERON:0001511	82.48	gold quality
dorsal root ganglion	UBERON:0000044	82.20	gold quality
pleura	UBERON:0000977	82.16	gold quality
coronary artery	UBERON:0001621	82.05	gold quality
body of stomach	UBERON:0001161	81.84	gold quality
visceral pleura	UBERON:0002401	81.77	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	81.60	gold quality
pylorus	UBERON:0001166	81.37	gold quality
parietal pleura	UBERON:0002400	81.36	gold quality
stomach	UBERON:0000945	81.17	gold quality
renal medulla	UBERON:0000362	80.90	gold quality
left coronary artery	UBERON:0001626	80.76	gold quality
palpebral conjunctiva	UBERON:0001812	80.72	gold quality
gingiva	UBERON:0001828	80.36	gold quality
urinary bladder	UBERON:0001255	80.19	gold quality
body of tongue	UBERON:0011876	80.07	gold quality
aorta	UBERON:0000947	79.94	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	79.93	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	79.73	gold quality
periodontal ligament	UBERON:0008266	79.52	silver quality
adenohypophysis	UBERON:0002196	79.24	gold quality
placenta	UBERON:0001987	78.92	gold quality
amniotic fluid	UBERON:0000173	78.91	gold quality
cortex of kidney	UBERON:0001225	78.70	gold quality
bone marrow	UBERON:0002371	78.44	gold quality
descending thoracic aorta	UBERON:0002345	78.27	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	78.21	gold quality
mammalian vulva	UBERON:0000997	77.50	gold quality

Single-cell (SCXA)

Detected in 32 experiment(s), a significant marker in 24.

Experiment	Marker?	Max mean expression
E-CURD-122	yes	1861.51
E-GEOD-134144	yes	1603.55
E-GEOD-114530	yes	1543.01
E-MTAB-11011	yes	1334.47
E-GEOD-130473	yes	1063.34
E-MTAB-8530	yes	950.87
E-CURD-6	yes	343.62
E-MTAB-7052	yes	160.02
E-HCAD-1	yes	55.25
E-CURD-88	yes	45.46
E-GEOD-135922	yes	30.41
E-MTAB-8410	yes	24.91
E-HCAD-4	yes	22.93
E-MTAB-10553	yes	19.22
E-CURD-46	yes	18.66

HPA expression

RNA tissue specificity: Low tissue specificity

showing 60 of 79 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Bone marrow	tissue	409.7	not detected
Adipose tissue	tissue	369.6	medium
Smooth muscle	tissue	330.5	not detected
Gallbladder	tissue	324.8	low
Thyroid gland	tissue	296.7	medium
Urinary bladder	tissue	199.2	high
Ovary	tissue	197.2	medium
Esophagus	tissue	176.8	low
Fallopian tube	tissue	150.3	low
Thymus	tissue	142.7
Cervix	tissue	140.8	low
Pancreas	tissue	119.1	not detected
Adrenal gland	tissue	114.8	not detected
Appendix	tissue	111.8	low
Prostate	tissue	111.1	not detected
Lung	tissue	106.9	not detected
Breast	tissue	86.1	not detected
Liver	tissue	79.9	not detected
Tongue	tissue	76.0
Rectum	tissue	73.8	low
Salivary gland	tissue	72.5	medium
Lymph node	tissue	63.3	medium
Small intestine	tissue	59.3	not detected
Placenta	tissue	54.2	high
Stomach 1	tissue	43.7	not detected
Endometrium 1	tissue	43.6	not detected
Parathyroid gland	tissue	43.4	not detected
Heart muscle	tissue	42.6	not detected
Colon	tissue	35.2	not detected
Kidney	tissue	32.5	low
Seminal vesicle	tissue	27.9	not detected
Pituitary gland	tissue	25.3
Duodenum	tissue	23.3	not detected
Spinal cord	tissue	23.1
Spleen	tissue	20.6	medium
Choroid plexus	tissue	13.5
Olfactory bulb	tissue	12.6
Nucleus accumbens	tissue	12.3
Cerebellum	tissue	11.2	not detected
Postcentral gyrus	tissue	10.7
Retina	tissue	10.0
Testis	tissue	8.3	not detected
Vagina	tissue	8.3	low
Hippocampus	tissue	6.5	not detected
Cerebral cortex	tissue	6.2	not detected
Retrosplenial cortex	tissue	6.2
Hippocampal formation	tissue	5.6
Entorhinal cortex	tissue	5.6
Occipital cortex	tissue	5.5
Prefrontal cortex	tissue	5.3
Retrosplenial and cingulate cortex	tissue	5.2
Insular cortex	tissue	5.2
Basal ganglia	tissue	4.9	not detected
Somatosensory cortex	tissue	4.9
Locus coeruleus	tissue	4.8
Frontal cortex	tissue	4.7
Temporal cortex	tissue	4.5
Motor cortex	tissue	4.0
Ventral forebrain	tissue	4.0
Superior colliculi	tissue	3.9

Brain sub-regions (HPA Brain Atlas): detected in 189; highest nTPM — Blood vessel (80.5), Flocculonodular lobe (69.6), Hippocampus, CA1 (26.9), Dorsal spinal cord (23.1), Parietal operculum (22.7).

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

showing 30 of 43 targets:

Target	Regulation
ADAM2
ALB	Repression
AP1	Unknown
BGLAP	Activation
CCK	Activation
CCN2	Activation
CCND1	Activation
CCNE1	Unknown
CD14	Activation
CD9	Activation
CDK2	Unknown
CDK5	Activation
COL3A1	Activation
CREB1	Activation
CXCL8	Activation
DNAJB4
DRD2	Activation
FASLG	Activation
FOS	Unknown
FOSB	Unknown
GFAP	Activation
GRIN1	Activation
GRIN2A	Activation
IL11	Activation
IL2	Activation
ITGA2B	Activation
LGALS1	Activation
MAP2	Repression
MMP2	Activation
MYC	Activation

JASPAR motifs

Motif	Name	Family
MA1127.1	FOSB::JUN	Fos-related,Jun-related
MA1135.1	FOSB::JUNB	Fos-related,Jun-related
MA1135.2	FOSB::JUNB	Fos-related,Jun-related
MA1136.1	FOSB::JUNB	Fos-related,Jun-related
UN0122.1	FOSB	Fos-related
UN0122.2	FOSB	Fos-related
UN1112.1	CEBPB::FOSB	CEBP-related,Fos-related
UN1124.1	CEBPE::FOSB	CEBP-related,Fos-related

JASPAR matrix evidence (PMIDs): PMID:11988758

Upstream regulators (CollecTRI, top): AP1, CEBPA, CREB1, ESR1, FOS, FOSB, FOXC1, RELA, SP1, SRF, STAT6

miRNA regulators (miRDB)

Targeting FOSB by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 87 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5193	100.00	67.26	1744
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-1-3P	99.93	72.35	1914
HSA-MIR-206	99.93	72.50	1893
HSA-MIR-613	99.91	71.50	1710
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6756-5P	99.82	67.97	2466
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6842-5P	99.80	67.54	1587
HSA-MIR-7110-5P	99.80	67.84	1712
HSA-MIR-204-5P	99.79	71.62	2439
HSA-MIR-211-5P	99.79	71.65	2440
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-149-3P	99.72	68.22	3963

Functional genomics

gnomAD constraint: pLI 0.951, LOEUF 0.534, missense Z 1.19 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD)

ENST00000353609 splits into 3 regions with different missense tolerance; 0 are missense-constrained. Missense variants in a constrained region (low observed/expected) are more likely to be pathogenic. gnomAD

Region (GRCh38)	Missense obs / exp	o/e	Constrained
19:45,468,587–45,470,949	193 / 207.1	0.93	no
19:45,471,194–45,472,635	35 / 83.5	0.42	no
19:45,472,636–45,473,009	148 / 170.0	0.87	no

Literature-anchored findings (GeneRIF, showing 40)

• demonstrated that a functional AP-1 site mediates MMP-2 transcription in cardiac cells through the binding of distinctive Fra1-JunB and FosB-JunB heterodimers. The synthesis of MMP-2 is considered to be independent of the AP-1 transcriptional complex (PMID:12371906)
• AP-1 (c-Jun & FosB) binds to a site in the 5’ untranslated region of the CD95L gene. Transdominant negative Jun mutants reduce CD95L promoter activity. FosB dimerized with c-Jun has an important role in TCR/CD3-mediated activation-induced cell death. (PMID:12618758)
• VEGF and PlGF induced expression of both full-length FosB mRNA and an alternatively spliced variant. (PMID:14741347)
• In hepatoma-associated anorexia-cachexia FpsB was induced in several brain areas of thes forebrain. (PMID:15926923)
• Coordinated down- and up-regulation of the various AP-1 subunits in the course of epidermal wound healing is important for its undisturbed progress, putatively by influencing inflammation and cell-cell communication. (PMID:17495958)
• activation of protein kinase A elicits an immediate response through induction of genes such as ID2 and FosB, followed by sustained secretion of bone-related cytokines such as BMP-2, IGF-1, and IL-11 (PMID:18490653)
• DeltaFosB was able to trigger partial Pref-1-mediated de-differentiation of adipocytes, which also retained their adipocytic cell phenotype. (PMID:18491952)
• An IFN-gamma-mediated homeostatic loop limits the potential for tissue damage associated with inflammation and identifies transcriptional factor AP-1 that regulates matrix metalloproteinase expression in myeloid cells in inflammatory settings. (PMID:18802113)
• MicroRNA-101, which is aberrantly expressed in hepatocellular carcinoma, could repress the expression of the FOS oncogene. (PMID:19133651)
• FosB is induced in PMA treated K562 cells in a sustained manner and forms an active AP-1 protein-DNA complex. Down-regulation of FosB with specific shRNAs inhibited the induction of CD41, a specific cell surface marker of megakaryocytes. (PMID:19381435)
• Results suggest that in addition to clinically prognostic factors, FOS-B expression has a debatable impact on patient survival. (PMID:19795327)
• RGS16 and FosB are underexpressed in pancreatic cancer with lymph node metastasis and associated with reduced survival (PMID:20571966)
• transcription factor FosB/activating protein-1 (AP-1) activation is a prominent downstream signal of the extracellular nucleotide receptor P2RX7 in monocytic and osteoblastic cells (PMID:20813842)
• Findings indicate that neurobehavioral stress leads to FosB-driven increases in IL8, which is associated with increased tumor growth and metastases. (PMID:20826776)
• AP-1 protein induction during monopoiesis favors C/EBP: AP-1 heterodimers over C/EBP homodimerization and stimulates FosB transcription. (PMID:21543584)
• Induction of a DeltaFOSB mediated transcriptional pattern in the prefrontal cortex is opposite to the down-regulation observed in the nucleus accumbens in patients with major depressive disorder (PMID:21616539)
• Report Fos-B expression in skin keratinocytes/fibroblasts and keloid fibroblasts exposed to genistein. (PMID:23614275)
• Data indicate a significant correlation in miR-181b, FOS and miR-21 expression glioma tissues. (PMID:23810250)
• This study describing the expres-sion pattern of FosB/ FosB immunoreactivity inpost mortem basal ganglia sections from Parkinson disease patients. (PMID:23933656)
• Pseudomyogenic haemangioendothelioma consistently displays a SERPINE1-FOSB fusion gene, resulting from a translocation between chromosomes 7 and 19. (PMID:24374978)
• The abnormalities were screened by FISH in 44 epithelioid hemangioma (EH) from different locations with seven additional EH revealing FOSB gene rearrangements, all except one being fused to ZFP36. (PMID:25043949)
• studies of FosB are providing new insight into the molecular basis of depression and antidepressant action. (PMID:25446562)
• our findings show that DeltaFosB increases the expression of MMP-9 and exhibits a significantly high survival and proliferation in MCF-7 cells. (PMID:26608367)
• These results suggest that SETDB1- mediated FosB expression is a common molecular phenomenon, and might be a novel pathway responsible for the increase in cell proliferation that frequently occurs during anticancer drug therapy. (PMID:26949019)
• FOSB overexpression results in TNBC cell death, whereas inhibition of calcium signaling eliminates FOSB induction and blocks TP4-induced TNBC cell death (PMID:27248170)
• FosB expression in the prefrontal cortex and hippocampus of the cocaine addicted and depression patients (PMID:27494187)
• Diffuse and strong FOSB expression was specific for pseudomyogenic hemangioendothelioma in the current series and FOSB immunohistochemistry is an effective tool for differentiating between PHE and its histological mimics. (PMID:27515856)
• Our results using a number of approaches, such as promoter reporter assay, FosB knock down and Chip assay, suggest that the expression of miR-22 is regulated transcriptionally by FosB. (PMID:27889568)
• FOSB is a highly sensitive and diagnostically useful marker for pseudomyogenic hemangioendothelioma. (PMID:28009608)
• results shows the involvement of Spry2 in regulation of FosB and Runx2 genes, MAPK signaling and proliferation of mesenchymal stem cells. (PMID:28387432)
• The NFATc3 first induced the expression of its interaction partner FosB before forming the heterodimeric NFATc3-FosB transcription factor complex, which bound the proximal AP-1 site in the TF gene promoter and activated TF expression. (PMID:28724635)
• the mechanism underlying redox-regulation of AP-1 Fos/Jun transcription factors and provide structural insight for therapeutic interventions targeting AP-1 proteins. (PMID:28981703)
• FOSB immunohistochemistry is sensitive in the diagnosis of angiolymphoid hyperplasia with eosinophilia, and allows differentiation from its histological mimics (PMID:29527734)
• Findings iindicate a human bone tumour defined by mutations of FOS and FOSB. (PMID:29858576)
• Recurrent ACTB-FOSB fusions are found in pseudomyogenic hemangioendothelioma. (PMID:30256258)
• Recurrent ACTB-FOSB fusion occurs in pseudomyogenic hemangioendothelioma. (PMID:30459475)
• We identified increased level of Fos-B mRNA, the binding target of FUS, in FUS-mutant MNs. While Fos-B reduction using si-RNA or an inhibitor ameliorated the observed aberrant axon branching, Fos-B overexpression resulted in aberrant axon branching even in vivo. The commonality of those phenotypes was further confirmed with other amyotrophic lateral sclerosis (ALS) causative mutation than FUS (PMID:31262712)
• Poly(ADP-ribose) Polymerases (PARP) cleavage and positive annexin V level are increased during piperlongumine (PL) treatment with FosB overexpression in MCF7 breast cancer cells, whereas PARP cleavage and positive annexin V level were decreased during PL treatment with siFosB transfection, implying that FosB is a pro-apoptotic protein for induction of cell death in PL-treated MCF7 breast cancer cells. (PMID:31735020)
• Association of FOSB exon 4 unmethylation with poor prognosis in patients with latestage nonsmall cell lung cancer. (PMID:31894310)
• Clinicopathologic study of 6 cases of epithelioid osteoblastoma of the jaws with immunoexpression analysis of FOS and FOSB. (PMID:32482537)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	fosb	ENSDARG00000055751
mus_musculus	Fosb	ENSMUSG00000003545
rattus_norvegicus	Fosb	ENSRNOG00000046667
drosophila_melanogaster	Atf3	FBGN0028550

Paralogs (8): FOSL2 (ENSG00000075426), BATF3 (ENSG00000123685), JDP2 (ENSG00000140044), BATF (ENSG00000156127), ATF3 (ENSG00000162772), BATF2 (ENSG00000168062), FOS (ENSG00000170345), FOSL1 (ENSG00000175592)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:95575) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 24 distinct phenotype terms.

Mouse phenotype (MP)	Records
decreased bone mineral density	1
decreased body length	1
decreased body size	1
increased anxiety-related response	1
decreased anxiety-related response	1
abnormal nursing	1
abnormal pup retrieval	1
abnormal maternal nurturing	1
increased exploration in new environment	1
abnormal seizure response to electrical stimulation	1
reduced NMDA-mediated synaptic currents	1
abnormal skin morphology	1
abnormal learning/memory/conditioning	1
abnormal parental behavior	1
abnormal kidney morphology	1
abnormal emotion/affect behavior	1
decreased mean corpuscular volume	1
enlarged kidney	1
abnormal frequency of paradoxical sleep	1
abnormal locomotor activation	1
abnormal depression-related behavior	1
tonic-clonic seizures	1
impaired spatial learning	1
increased locomotor activity	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Gallus gallus	P11939	100.0%	Diamond
Ovis aries	O02761	99.0%	Diamond
Mesocricetus auratus	O88479	97.6%	Diamond
Cricetiscus campbelli	Q56TT7	97.6%	Diamond
Phodopus roborovskii	Q56TN0	97.4%	Diamond
Bos taurus	O77628	97.1%	Diamond
Felis catus	Q8HZP6	97.1%	Diamond
Cricetulus griseus	Q9Z2Q8	96.9%	Diamond
Sus scrofa	O97930	96.8%	Diamond
Canis lupus familiaris	Q9TUB3	90.8%	Diamond
Drosophila yakuba	B4PPK2	88.0%	Diamond
Takifugu rubripes	P53450	87.2%	Diamond
Dichotomyctere fluviatilis	Q91496	87.2%	Diamond
Drosophila simulans	B4R090	85.7%	Diamond
Drosophila erecta	B3P5D2	83.3%	Diamond
Cyprinus carpio	P79702	55.9%	Diamond
Avian retrovirus NK24	P23050	100.0%	Diamond
FBJ murine osteosarcoma virus	P01102	98.5%	Diamond
Finkel-Biskis-Jinkins murine sarcoma virus	P29176	89.5%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
PPP1R13L	protein-coding	10848
POLR1G	protein-coding	10849
ERCC1	protein-coding	2067
TRU-TCA1-1	tRNA	7234
MIR6088	ncRNA	102464836
KLC3	protein-coding	147700
ERCC2	protein-coding	2068
RTN2	protein-coding	6253
OPA3-RTN2	protein-coding	144667540
PPM1N	protein-coding	147699
VASP	protein-coding	7408

Protein

Protein identifiers

Protein FosB — P53539 (reviewed: P53539)

Alternative names: FosB proto-oncogene, AP-1 transcription factor subunit, G0/G1 switch regulatory protein 3, Transcription factor AP-1 subunit FosB

All UniProt accessions (4): K7EJ89, K7EKA0, K7ERZ8, P53539

UniProt curated annotations — full annotation on UniProt →

Function. Heterodimerizes with proteins of the JUN family to form an AP-1 transcription factor complex, thereby enhancing their DNA binding activity to gene promoters containing an AP-1 consensus sequence 5’-TGA[GC]TCA-3’ and enhancing their transcriptional activity. As part of the AP-1 complex, facilitates enhancer selection together with cell-type-specific transcription factors by collaboratively binding to nucleosomal enhancers and recruiting the SWI/SNF (BAF) chromatin remodeling complex to establish accessible chromatin. Together with JUN, plays a role in activation-induced cell death of T cells by binding to the AP-1 promoter site of FASLG/CD95L, and inducing its transcription in response to activation of the TCR/CD3 signaling pathway. Exhibits transactivation activity in vitro. Involved in the display of nurturing behavior towards newborns. May play a role in neurogenesis in the hippocampus and in learning and memory-related tasks by regulating the expression of various genes involved in neurogenesis, depression and epilepsy. Implicated in behavioral responses related to morphine reward and spatial memory. Exhibits lower transactivation activity than isoform 1 in vitro. The heterodimer with JUN does not display any transcriptional activity, and may thereby act as an transcriptional inhibitor. May be involved in the regulation of neurogenesis in the hippocampus. May play a role in synaptic modifications in nucleus accumbens medium spiny neurons and thereby play a role in adaptive and pathological reward-dependent learning, including maladaptive responses involved in drug addiction. Seems to be more stably expressed with a half-life of ~9.5 hours in cell culture as compared to 1.5 hours half-life of isoform 1.

Subunit / interactions. Heterodimer; binds to DNA as heterodimer. Component of an AP-1 transcription factor complex; composed of FOS-JUN heterodimers. As part of the AP-1 transcription factor complex, forms heterodimers with JUN, JUNB or JUND, thereby binding to the AP-1 consensus sequence and stimulating transcription. Interacts with the BAF multiprotein chromatin-remodeling complex subunits SMARCB1 and SMARCD1. Interacts with ARID1A and JUN. Homodimer under oxidizing conditions and monomer under reducing conditions (in vitro). Heterodimer; binds to DNA as heterodimer. Forms heterodimers with JUNB, JUN or JUND; thereby binding to the AP-1 consensus sequence but does not stimulate transcription. Forms heterodimers with JUND under oxidizing conditions.

Subcellular location. Nucleus.

Tissue specificity. Expressed in the nucleus accumbens of the striatum (at protein level).

Post-translational modifications. Phosphorylated. Phosphorylated at Ser-27 by CSNK2A1; phosphorylation increases protein stability and transactivation potential.

Domain organisation. Binds DNA via bZIP domain; DNA-binding is under control of cellular redox homeostasis (in vitro). To enable DNA binding, the bZIP domain must undergo a conformational rearrangement which requires the reduction of the interchain disulfide bond between FosB and JunD (in vitro). The bZIP domain is able to form homomeric oligomers via formation of interchain disulfide bonds under non-reducing conditions (in vitro). Under reducing conditions, the disulfide-bonded homomeric species dissociates into monomers (in vitro).

Similarity. Belongs to the bZIP family. Fos subfamily.

Isoforms (11)

UniProt ID	Names	Canonical?
P53539-1	1, FosB-L	yes
P53539-2	2
P53539-3	3
P53539-4	4
P53539-5	5
P53539-6	6
P53539-7	7
P53539-8	8
P53539-9	9
P53539-10	10
P53539-11	11, deltaFosB

RefSeq proteins (3): NP_001107643, NP_001397998, NP_006723* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000837	AP-1	Family
IPR004827	bZIP	Domain
IPR046347	bZIP_sf	Homologous_superfamily

Pfam: PF00170

UniProt features (26 total): compositionally biased region 7, splice variant 6, region of interest 6, chain 1, domain 1, modified residue 1, disulfide bond 1, sequence variant 1, sequence conflict 1, helix 1

Structure

Experimental structures (PDB)

12 structures by resolution:

PDB	Title	Method	Resolution (Å)
9OC3	Transcription factor DeltaFOSB/JUND bZIP domain in complex with an effector molecule	X-RAY DIFFRACTION	1.73
7UCC	Transcription factor FosB/JunD bZIP domain in the reduced form	X-RAY DIFFRACTION	1.94
5VPE	Transcription factor FosB/JunD bZIP domain in complex with cognate DNA, type-I crystal	X-RAY DIFFRACTION	2.05
6UCI	Transcription factor DeltaFosB bZIP domain self-assembly, oxidized form	X-RAY DIFFRACTION	2.09
6UCL	Transcription factor deltaFosB bZIP domain self-assembly, type-I crystal	X-RAY DIFFRACTION	2.21
6UCM	Transcription factor DeltaFosB bZIP domain self-assembly, type-II crystal	X-RAY DIFFRACTION	2.42
5VPC	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-II crystal	X-RAY DIFFRACTION	2.5
5VPB	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-I crystal	X-RAY DIFFRACTION	2.69
5VPF	Transcription factor FosB/JunD bZIP domain in complex with cognate DNA, type-II crystal	X-RAY DIFFRACTION	2.69
5VPD	Transcription factor FosB/JunD bZIP domain in its oxidized form, type-III crystal	X-RAY DIFFRACTION	2.79
5VPA	Transcription factor FosB/JunD bZIP domain	X-RAY DIFFRACTION	2.83
7UCD	Transcription factor FosB/JunD bZIP domain covalently modified with the …	X-RAY DIFFRACTION	3.21

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P53539-F1	60.79	0.21

Human Protein Atlas

Protein class: Predicted intracellular proteins, Transcription factors, Basic domains

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): nucleoplasm; vesicles

Antibody reliability (HPA): IH approved · IF supported

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1)

Type	Positions
Phosphoserine	27

Disulfide bonds (1)

Type	Positions
Interchain (with c-285 in jund)	172

Function

Pathways and Gene Ontology

Reactome pathways

2 curated (TAS) of 11; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

11 pathways:

ID	Pathway	Evidence
R-HSA-9018519	Estrogen-dependent gene expression	curated
R-HSA-9909649	Regulation of PD-L1(CD274) transcription	curated
R-HSA-8939211	ESR-mediated signaling	—
R-HSA-9031628	NGF-stimulated transcription	electronic
R-HSA-198725	Nuclear Events (kinase and transcription factor activation)	—
R-HSA-162582	Signal Transduction	—
R-HSA-187037	Signaling by NTRK1 (TRKA)	—
R-HSA-166520	Signaling by NTRKs	—
R-HSA-9006931	Signaling by Nuclear Receptors	—
R-HSA-9006934	Signaling by Receptor Tyrosine Kinases	—
R-HSA-9938024	Somatic hypermutation of immunoglobulin genes	electronic

MSigDB gene sets: 398 (showing top): GSE45365_HEALTHY_VS_MCMV_INFECTION_CD8_TCELL_IFNAR_KO_DN, GSE45365_NK_CELL_VS_BCELL_UP, ATF_B, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_RESPONSE_TO_ETHANOL, KANG_DOXORUBICIN_RESISTANCE_UP, CHIBA_RESPONSE_TO_TSA_UP, GGTGTGT_MIR329, GOBP_BEHAVIOR, TGCGCANK_UNKNOWN, GOBP_RESPONSE_TO_COCAINE, GOBP_RESPONSE_TO_AMINE, REACTOME_ADAPTIVE_IMMUNE_SYSTEM, FISCHER_G1_S_CELL_CYCLE, GOBP_RESPONSE_TO_CORTICOSTEROID

GO Biological Process (18): negative regulation of transcription by RNA polymerase II (GO:0000122), response to amphetamine (GO:0001975), regulation of transcription by RNA polymerase II (GO:0006357), transcription by RNA polymerase II (GO:0006366), female pregnancy (GO:0007565), response to xenobiotic stimulus (GO:0009410), response to mechanical stimulus (GO:0009612), response to progesterone (GO:0032570), cellular response to hormone stimulus (GO:0032870), response to nicotine (GO:0035094), response to morphine (GO:0043278), response to ethanol (GO:0045471), behavioral response to cocaine (GO:0048148), response to corticosterone (GO:0051412), response to cAMP (GO:0051591), regulation of DNA-templated transcription (GO:0006355), response to cocaine (GO:0042220), positive regulation of transcription by RNA polymerase II (GO:0045944)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), DNA binding (GO:0003677), sequence-specific double-stranded DNA binding (GO:1990837), double-stranded DNA binding (GO:0003690), DNA-binding transcription factor activity (GO:0003700), protein binding (GO:0005515), sequence-specific DNA binding (GO:0043565)

GO Cellular Component (4): chromatin (GO:0000785), nucleus (GO:0005634), nucleoplasm (GO:0005654), cytosol (GO:0005829)

Reactome top-level categories

9 top-level categories:

Category	Pathways
Signal Transduction	2
ESR-mediated signaling	1
Nuclear Events (kinase and transcription factor activation)	1
Regulation of PD-L1(CD274) expression	1
Affinity selection of immunoglobulins	1
Signaling by Receptor Tyrosine Kinases	1
Signaling by NTRKs	1
Signaling by NTRK1 (TRKA)	1
Signaling by Nuclear Receptors	1

GO top-level categories

48 GO namespaces:

Category	Terms
regulation of transcription by RNA polymerase II	3
transcription by RNA polymerase II	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
cellular anatomical structure	3
regulation of DNA-templated transcription	2
DNA-templated transcription	2
response to chemical	2
response to ketone	2
response to alcohol	2
response to oxygen-containing compound	2
DNA binding	2
negative regulation of DNA-templated transcription	1
response to amine	1
multi-organism reproductive process	1
multi-multicellular organism process	1
response to external stimulus	1
response to abiotic stimulus	1
response to steroid hormone	1
response to hormone	1
cellular response to chemical stimulus	1
cellular response to endogenous stimulus	1
response to isoquinoline alkaloid	1
adult behavior	1
response to cocaine	1
response to glucocorticoid	1
response to mineralocorticoid	1
response to purine-containing compound	1
response to organophosphorus	1
regulation of gene expression	1
regulation of RNA biosynthetic process	1
response to alkaloid	1
positive regulation of DNA-templated transcription	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
DNA-binding transcription factor activity, RNA polymerase II-specific	1
DNA-binding transcription activator activity	1
positive regulation of transcription by RNA polymerase II	1
nucleic acid binding	1
double-stranded DNA binding	1
sequence-specific DNA binding	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
binding	1
chromosome	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cytoplasm	1

Experimentally-supported GO annotations

GO terms backed by direct experimental evidence (ECO experimental codes) — 3 of 31 annotations. The rest are phylogenetic / computational / electronic (IEA).

3 experimentally-supported GO terms:

GO term	NS	Evidence
nucleoplasm	CC	direct assay
nucleus	CC	direct assay
sequence-specific double-stranded DNA binding	MF	direct assay

Protein interactions and networks

STRING

showing 15 of 2,250 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FOSB	JUND	P17535	896
FOSB	JUN	P05412	863
FOSB	EGR1	P18146	835
FOSB	FOSL1	P15407	800
FOSB	FOSL2	P15408	792
FOSB	EGR3	Q06889	764
FOSB	FOS	P01100	725
FOSB	EGR2	P11161	721
FOSB	NR4A1	P22736	666
FOSB	EHMT2	Q96KQ7	664
FOSB	SYT14	Q8NB59	660
FOSB	NPAS4	Q8IUM7	648
FOSB	SYT16	Q17RD7	637
FOSB	CDK5	Q00535	591
FOSB	DUSP12	Q9UNI6	588

IntAct

Human interaction partners of FOSB in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

25 partners by confidence:

Partner	Interaction type	MIscore	Records
JUNB	physical association	0.740	5
JUN	association	0.690	2
ATF2	physical association	0.670	3
NFE2L2	physical association	0.630	6
POU6F2	physical association	0.560	5
TENT5B	physical association	0.560	5
AGXT	physical association	0.560	3
CENPO	physical association	0.560	3
CREB5	physical association	0.560	3
CYTH4	physical association	0.560	3
ENKD1	physical association	0.560	3
FAM222B	physical association	0.560	3
FAM90A1	physical association	0.560	3
FOXP3	physical association	0.560	3
GLIS2	physical association	0.560	3
NCK2	physical association	0.560	3
NEDD9	physical association	0.560	3
PHC2	physical association	0.560	3
PHF1	physical association	0.560	3
POGZ	physical association	0.560	3
ROR2	physical association	0.560	3
TLE5	physical association	0.560	3
TLX3	physical association	0.560	3
VEZF1	physical association	0.560	3
ZC3H10	physical association	0.560	3

BioGRID (74 interactions; top human partners by supporting records): JUN (Affinity Capture-MS; 5 records), JUNB (Affinity Capture-MS; 5 records), NFE2L2 (Two-hybrid; 3 records), ATF2 (Two-hybrid; 2 records), CREB5 (Two-hybrid; 2 records), LINC00963 (Protein-RNA; 2 records), MIDN (Affinity Capture-MS; 2 records), AES (Two-hybrid), AGXT (Two-hybrid), APEX1 (Affinity Capture-RNA), ATF7 (Affinity Capture-MS), AUH (Affinity Capture-MS), BAG3 (Affinity Capture-Luminescence), CBL (Positive Genetic), CEBPE (Negative Genetic)

SIGNOR signaling

3 signaling interactions:

A	Effect	B	Mechanism
CSNK2A1	up-regulates	FOSB	phosphorylation
(-)-anisomycin	up-regulates	FOSB	“chemical activation”
N	“up-regulates quantity by expression”	FOSB	“transcriptional regulation”

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
FOSB-JUND-SMAD3-SMAD4 complex	4	FOSB, JUND, SMAD3, SMAD4

Disease & clinical

Genetic variants

Variant evidence for FOSB: 44 ClinVar records (0 pathogenic / likely pathogenic); 1 CIViC cancer variant; 5 GWAS associations.

ClinVar

44 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	37
Likely benign	2
Benign	1

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 23 predictions of 332):

Position(s)	Effect	Δscore	Sites
19:45470950	donor_loss	1.0000	2
19:45471186	acceptor_gain	1.0000
19:45471192–45471193	acceptor_loss	1.0000	5
19:45471302–45471303	donor_loss	1.0000	3
19:45472526	acceptor_gain	1.0000
19:45472533–45472534	acceptor_gain	1.0000	2
19:45472542–45472543	acceptor_gain	1.0000	2
19:45468713–45468714	donor_loss	0.9900	3
19:45470950–45470951	donor_loss	0.9900	3
19:45471193	acceptor_loss	0.9900

AlphaMissense

796 missense substitutions predicted likely pathogenic (of 2,158 scored), across 188 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N165	8	1.000	1.000
H218	8	0.997	1.000
F54	8	0.984	0.999
D66	8	0.969	0.996
D188	8	0.938	0.990
D181	8	0.921	0.991
N174	8	0.885	0.992
S64	8	0.875	0.998
D95	8	0.847	0.941
C172	7	1.000	1.000
R173	7	1.000	1.000
C222	7	0.998	0.999
W69	7	0.995	1.000
E163	7	0.993	0.999
F213	7	0.969	0.990
E154	7	0.968	0.998
E191	7	0.962	0.991
K166	7	0.958	1.000
F2	7	0.955	0.986
R159	7	0.953	0.997

HPA cancer prognostics

RNA cancer specificity: Low cancer specificity

Human Protein Atlas survival analysis — favorable = higher expression predicts better survival.

3 prognostic cancer types:

Cancer	Prognostic	p-value
Kidney Renal Clear Cell Carcinoma (validation)	favorable	1.07e-07
Kidney Renal Clear Cell Carcinoma (TCGA)	favorable	0.000368
Breast Invasive Carcinoma (validation)	favorable	0.000637

Disease associations

OMIM: gene MIM:164772 | disease phenotypes:

GWAS associations

5 associations:

Study	Trait	p-value
GCST007827_3	Alzheimer’s disease or HDL levels (pleiotropy)	1e-97
GCST006979_504	Heel bone mineral density	2e-16
GCST006288_575	Heel bone mineral density	3e-12
GCST006979_503	Heel bone mineral density	5e-12
GCST006288_291	Heel bone mineral density	3e-6

EFO canonical traits (from GWAS)

2 canonical traits:

EFO ID	Trait name
EFO:0009270	heel bone mineral density
EFO:0004612	high density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL4630755 (PROTEIN COMPLEX), CHEMBL4630821 (SINGLE PROTEIN)

CIViC curated variants (1)

Named clinical variants curated in CIViC for this gene (the catalogue beneath the predictive evidence above):

Rearrangement.

PharmGKB: 1 entry (CPIC guideline: no)

Binding affinities (BindingDB)

1 measured of 12 human assays (13 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL4640716	IC50	58000 nM

CTD chemical–gene interactions

111 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	increases activity, increases expression, decreases expression, decreases methylation, affects cotreatment (+1 more)	8
Cadmium Chloride	affects cotreatment, increases expression	5
Benzo(a)pyrene	affects methylation, increases expression, increases methylation	4
Silicon Dioxide	increases expression	4
Dronabinol	decreases expression, decreases reaction, increases expression	4
Air Pollutants	increases abundance, increases expression, affects expression	3
Benzene	decreases expression	3
Cadmium	decreases expression, increases expression	3
Formaldehyde	increases expression	3
Nickel	increases expression	3
Tetrachlorodibenzodioxin	decreases reaction, increases expression, affects expression	3
Asbestos, Crocidolite	affects expression, increases expression	3
Particulate Matter	increases abundance, increases expression	3
cylindrospermopsin	increases expression	2
Estradiol	affects cotreatment, decreases expression, increases expression	2
Hydrogen Peroxide	affects expression, increases expression	2
Ozone	increases expression, affects expression, increases abundance	2
Silver	decreases expression, increases expression	2
Tetradecanoylphorbol Acetate	increases expression	2
Tobacco Smoke Pollution	increases expression	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	affects expression, increases expression	2
Thapsigargin	increases expression	2
aristolochic acid I	increases expression	1
bisphenol F	increases expression	1
methylmercuric chloride	increases expression	1
triphenyl phosphate	affects expression	1
deoxynivalenol	affects cotreatment, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
hydroxyhydroquinone	increases expression	1
beta-lapachone	increases expression	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4625230	Binding	Inhibition of recombinant Hi6-tagged deltaFOSB (unknown origin)/His6-tagged JUND (unknown origin) expressed in insect cells interaction with TAMRA labeled 5’-GTCGGTGACTCAAAACA-3’ AP1 oligonucleotide measured after 15 mins by fluorescence po	Discovery of phenanthridine analogues as novel chemical probes disrupting the binding of DNA to ΔFosB homodimers and ΔFosB/JunD heterodimers. — *Bioorg Med Chem Lett*

Cellosaurus cell lines

9 cell lines: 6 cancer cell line, 3 embryonic stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A1V3	SEES3-1V human FOSB, clone1	Embryonic stem cell	Male
CVCL_A1V4	SEES3-1V human FOSB, clone2	Embryonic stem cell	Male
CVCL_A1V5	SEES3-1V human FOSB, clone3	Embryonic stem cell	Male
CVCL_D1MK	Abcam K-562 FOSB KO	Cancer cell line	Female
CVCL_D2J5	Abcam Raji FOSB KO	Cancer cell line	Male
CVCL_E1XN	HAP1 FOSB (-) 1	Cancer cell line	Male
CVCL_E1XP	HAP1 FOSB (-) 2	Cancer cell line	Male
CVCL_E1XQ	HAP1 FOSB (-) 3	Cancer cell line	Male
CVCL_UQ52	Abcam Jurkat FOSB KO	Cancer cell line	Male

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for FOSB across ~30M SureChEMBL compounds — explore on Sugi Predict.